

Effect of Dose Modifications on Response to Duvelisib in Patients With Relapsed/Refractory CLL/SLL in the DUO Trial


Paolo Ghia,¹ Ian W. Flinn,^{2,3} Nicole Lamanna,⁴ Marco Montillo,⁵ Árpád Illés,⁶ Gabriel Etienne,⁷ Julio Delgado,⁸ Bryone J. Kuss,⁹ Constantine S. Tam,¹⁰ Fritz Offner,¹¹ Francesc Bosch,¹² Matthew S. Davids,¹³ Ulrich Jäger,¹⁴ Florence Cymbalista,¹⁵ David T. Weaver,¹⁶ Stephanie Lustgarten,¹⁶ Hagop Youssoufian,¹⁶ Stephan Stilgenbauer^{17,18}

¹Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy; ²Sarah Cannon Research Institute, Nashville, TN, USA; ³Tennessee Oncology, Nashville, TN, USA; ⁴NewYork-Presbyterian, Columbia University Medical Center, New York, NY, USA; ⁵Niguarda Cancer Center, Niguarda Hospital, Milan, Italy; ⁶University of Debrecen, Debrecen, Hungary; ⁷Institut Bergonie, Bordeaux, France; ⁸Hospital Clinic, Barcelona, Spain; ⁹Flinders Medical Centre—Flinders University, Bedford Park, SA, Australia; ¹⁰Peter MacCallum Cancer Centre, St Vincent's Hospital and University of Melbourne, Melbourne, VIC, Australia; ¹¹University Hospital Ghent, Ghent, Belgium; ¹²University Hospital Vall d'Hebron, Barcelona, Spain; ¹³Dana-Farber Cancer Institute, Boston, MA, USA; ¹⁴Medical University of Vienna, Vienna, Austria; ¹⁵Hôpital Avicenne, Paris, France; ¹⁶Verastem Oncology, Needham, MA, USA; ¹⁷University Hospital Ulm, Ulm, Germany; ¹⁸Klinik für Innere Medizin I, Universitätsklinikum des Saarlandes, Homburg, Germany

BACKGROUND

- Duvelisib (DUV) is a first-in-class oral dual phosphoinositide 3-kinase (PI3K)- δ,γ inhibitor approved by the US Food and Drug Administration for the treatment of patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after ≥ 2 prior therapies or R/R follicular lymphoma after ≥ 2 prior systemic therapies¹
- DUV targets key signaling pathways involved in the growth and survival of malignant B cells and the supportive tumor microenvironment²⁻⁵
- In the phase 3 DUO trial, DUV monotherapy 25 mg twice daily (BID) significantly improved efficacy vs ofatumumab (OFA) in patients with R/R CLL/SLL⁶
 - Median progression-free survival (mPFS): 13.3 vs 9.9 months (HR, 0.52; $P < .0001$) (Figure 1)
 - Overall response rate (ORR): 74% vs 45% ($P < .0001$)
- The adverse event (AE) profile with DUV monotherapy in patients with R/R CLL/SLL was consistent with previous reports and manageable with appropriate intervention via dose modifications, routine medical care, and prophylactic measures^{7,8}
- Here, we report results from retrospective analyses conducted to examine dose-modification patterns and their impact on response to DUV in the DUO trial

Figure 1. DUV Significantly Improved PFS vs OFA in Patients With R/R CLL/SLL⁶




METHODS

Study Design

- DUO (IPI-145-07; NCT02004522) is an open-label, 2-arm, randomized, phase 3, superiority trial designed to evaluate the efficacy and safety of DUV compared with OFA in patients who were diagnosed with R/R CLL/SLL (Figure 2)⁶
- Dose interruption (DI) or reduction (DR) to 15, 10, or 5 mg BID was permitted per study protocol to manage treatment-emergent adverse events (TEAEs)⁹

Figure 2. DUO Trial Design



IV, intravenous; PO, orally.
[†]A total of 312 patients had CLL; 7 patients had SLL (N = 319).
[‡]Patients received ≥ 1 prior therapy.
[§]Duvelisib was administered at 25 mg BID in 28-day treatment cycles until progressive disease or unacceptable toxicity.⁶


- TEAEs were defined as AEs that occurred from when the first dose of DUV was administered to 30 days after the last dose¹
- TEAEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 16.1⁸
- TEAE severity was assessed by investigators according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03⁸
- TEAEs of special interest (AESI) related to duvelisib were defined as groupings of infections, diarrhea, colitis, neutropenia, cutaneous reactions, alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) elevation, and pneumonitis⁸
- Response was assessed before and after dose modifications, and PFS was assessed in patients with and without dose modifications; response was analyzed using descriptive statistics, and PFS was estimated using Kaplan-Meier methods⁹
 - Response was assessed per IRC according to International Workshop on CLL (iwCLL)^{9,10} or International Working Group (IWG) Response Criteria,¹¹ with modification for treatment-related lymphocytosis
 - PFS was defined as time from randomization to first documentation of progressive disease (PD) as determined by an IRC or death due to any cause

RESULTS

Exposure and AESI

- Among 158 DUV-treated patients, the median duration of DUV exposure was 11.6 months (range, 0.2 to 36.8 months)
- The median overall DUV dose intensity (total dose taken/total expected dose [25 mg BID]) was 97.7 (range, 34.7 to 100)
 - Median dose intensity was highest during the first 3 months, then decreased slightly during months 3-6 (first 3 months, 100 [range, 6.6 to 100]; first 6 months, 93.3 [range, 3.3 to 100])
- Median time to onset across AESI after starting DUV ranged from 2.2 to 4.3 months (Figure 3A); median duration across AESI was up to 4 weeks (Figure 3B)
- Proportions of patients experiencing AESI were stable or decreased over time after 3 to 6 months (Table 1)

Figure 3. Onset and Duration of AESI



[†]The onset of hepatotoxicity is calculated using adverse event reported terms of hepatotoxicity. [‡]Grouped term for reactions with multiple preferred terms. [§]For patients with multiple events within an AESI category, time to onset is calculated for the first event in the category.

Table 1. Rates of AESI Over Time

AESI, n (%) [†]	0-3 Months n = 158	> 3-6 Months n = 137	> 6-9 Months n = 114	> 9-12 Months n = 100
Any-grade AESI	101 (64)	86 (63)	54 (47)	52 (52)
Infection	57 (36)	43 (31)	29 (25)	30 (30)
Neutropenia	33 (21)	21 (15)	13 (11)	11 (11)
Diarrhea/colitis	31 (20)	28 (20)	22 (19)	21 (21)
Cutaneous reactions	22 (14)	17 (12)	7 (6)	6 (6)
Hepatotoxicity (transaminase elevation)	8 (5)	9 (7)	4 (4)	3 (3)
Pneumonitis	4 (3)	6 (4)	0	2 (2)

[†]Grouped term for reactions with multiple preferred terms. [‡]Within each time period, patients were counted once for the first occurrence of an AESI grouping within the period; a patient may be counted multiple times for multiple time periods.

Dose Modification

- Baseline characteristics of patients with DI or DR are described in Table 2
- Among DUV-treated patients, DI occurred more frequently than DR (80% vs 27%)
 - In patients with DI, some had multiple DI (1 DI, 34%; 2 DI, 20%; ≥ 3 DI, 26%)
 - All patients with DR had only 1 DR; re-escalation to 25 mg BID occurred in 2 patients
- The median time to first DI and DR occurred within the first 6 months of DUV treatment (DI, 4 months [range, 0.1 to 25 months]; DR, 5 months [range, 1 to 23 months])
 - DI typically coincided with time to onset of AESI
 - The median durations of DI and DR were 2 weeks (range, 1 day to 19 weeks) and 17 weeks (range, 2 days to 98 weeks), respectively
- The most common AESI leading to DI or DR were diarrhea/colitis, infections, neutropenia, and cutaneous reactions (Table 3)
- Rates of AESI that occurred after DR are depicted in Figure 4
- Steroid treatment was required for management of AESI (diarrhea, n = 15; cutaneous reactions, n = 10; pneumonitis, n = 5)
- Individual AESI seldom led to discontinuation ($\leq 10\%$ of all DUV-treated patients [n = 158]): diarrhea/colitis, 10%; infection, 7%; cutaneous reactions, 4%; pneumonitis, 3%; neutropenia, 1%; transaminase elevation, 1%

Table 2. Baseline Characteristics for Patients With DI or DR

Characteristic	DUV	
	DI n = 126 [†]	DR n = 47 [†]
Median age (range), years	69 (40-86)	69 (40-86)
Median time since completion of most recent therapy (range), months	23 (0.8-149)	23 (1.2-149)
Bulky disease (≥ 5 cm target lesion), n (%)	54 (43)	21 (45)
Molecular features (per central laboratory), n (%)		
17p deletion	26 (21)	6 (13)
TP53 mutation	23 (18)	7 (15)
17p deletion and/or TP53 mutation	36 (29)	10 (21)
Unmutated IGHV	88 (70)	30 (64)
Median prior systemic therapies (range)	2 (1-10)	2 (1-7)
≥ 3 prior lines of therapy, n (%)	38 (31)	11 (23)


IGHV, immunoglobulin heavy variable.
[†]Intent-to-treat population.

Table 3. AESI Resulting in DI or DR

AESI, n (%) [†]	DUV n = 158	
	DI	DR
Diarrhea/colitis	45 (28)	13 (8)
Infection	43 (27)	4 (3)
Cutaneous reactions	20 (13)	7 (4)
Neutropenia	19 (12)	6 (4)
Hepatotoxicity (transaminase elevation)	9 (6)	5 (3)
Pneumonitis	7 (4)	2 (1)

[†]Grouped term for reactions with multiple preferred terms.

Figure 4. Rates of First AESI After DR



[†]Pneumonitis after DR, regardless of prior events. [‡]Grouped term for reactions with multiple preferred terms. [§]Percentage for first AESI after DR is based on the total number of patients who never had an AESI before their first DR.

Efficacy and Dose Modification

- Among responders (n = 118), median time to first response on DUV was 1.9 months, and estimated median duration of response was 11.1 months
- Response to DUV was improved or maintained in most patients evaluated for response who had ≥ 1 DI for > 1 week (84%) or > 2 weeks (82%) followed by ≥ 3 weeks on DUV (Table 4)
- Response to DUV was maintained in patients after a DR (≥ 30 days, 53%; ≥ 90 days, 45%; ≥ 120 days, 44%)
 - Among 25 patients who had a DR after a complete response (CR) or partial response (PR), the median time to DR was 5.6 months (range, 1 to 21.3 months), and the median duration at a reduced dose was 3.4 months

Table 4. Response in Patients With DI


Patients, n (%)	DUV	
	≥ 1 DI for > 1 Week Followed by ≥ 3 Weeks on DUV n = 50 [†]	≥ 1 DI for > 2 Weeks Followed by ≥ 3 Weeks on DUV n = 38 [†]
Response unchanged or improved after DI	42 (84)	31 (82)
PR to CR	0	0
SD to PR	5 (10)	2 (5)
CR to CR	0	0
PR to PR	26 (52)	19 (50)
SD to SD	6 (12)	6 (16)
Other [‡]	5 (10)	4 (11)
Progressed after DI	8 (16)	7 (18)
CR to PD	0	0
PR to PD	7 (14)	7 (18)
SD to PD	1 (2)	0

SD, stable disease.

[†]Response evaluable. [‡]Patients with documented evidence prior to DI with continued assessments of PD.


- PFS was similar between patients with ≥ 1 DI and those without DI for > 1 week or > 2 weeks within the first 3 months of therapy (mPFS: > 1 week, 17.8 vs 16.3 months; > 2 weeks, 17.8 vs 16.3 months) (Figure 5)
- PFS did not appear shorter in patients with DR vs those without DR within the first 3 and 6 months of therapy (Figure 6)

Figure 5. PFS in Patients With and Without DI Within the First 3 Months of Therapy



[†]Patients with PFS ≥ 3 months.

Figure 6. PFS in Patients With and Without DR Within the First 3 and 6 Months of Therapy



[†]Patients with PFS ≥ 3 months. [‡]Patients with PFS ≥ 6 months.

CONCLUSIONS

- DUV is a new, oral treatment option for patients with R/R CLL/SLL that has the potential for durable responses and good tolerability over time
- Response to DUV was rapid, occurring prior to first DI or DR in most patients
 - AESI coincided with median onset of DI and DR and in most cases did not lead to treatment discontinuation
- DI of > 1 week or DR did not negatively impact efficacy outcomes with DUV
- Taken together, these data suggest that DI/DR can contribute to the effective management of TEAEs with DUV in patients with R/R CLL/SLL

REFERENCES

- Copiktra (duvelisib) [package insert]. Needham, MA: Verastem, Inc; 2018.
- Chen S-S, et al. ASH 2015 [abstract 1753].
- Chen S-S, et al. ASH 2018 [abstract 4420].
- Casulo C, et al. ASCO 2016 [abstract 216].
- Pachter JA, Weaver DT. ASCO-SITC 2018 [abstract P33].
- Flinn IW, et al. Blood. 2018;132(23):2446-2455.
- Flinn IW, et al. Am J Hematol. 2018;93(11):1311-1317.
- Flinn IW, et al. J Clin Oncol. 2019;37(11):912-922.
- Hallek M, et al. Blood. 2008;111(12):5446-5456.
- Cheson BD, et al. J Clin Oncol. 2012;30(23):2820-2822.
- Cheson BD, et al. J Clin Oncol. 2007;25(5):579-586.

ACKNOWLEDGMENTS

Editorial and writing support was provided by Larra Yuelling, PhD, of Chrysalis Medical Communications, Inc, and funded by Verastem Oncology.

Copies of this poster obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permission from EHA and the author of this poster.

For questions, please contact 877-7RX-VSTM.



GET POSTER PDF